year
antivir
research
celebr
birthday
azidothymidin
azt
first
hiv
medicin
stimulu
numer
scientist
drug
compani
engag
antivir
drug
discoveri
sinc
wit
approv
hiv
drug
direct
toward
viral
protein
except
coreceptor
antagonist
maraviroc
antiretrovir
combin
therapi
transform
live
affect
individu
turn
hiv
infect
death
sentenc
manag
chronic
diseas
nevertheless
hivinfect
person
still
excess
mortal
risk
furthermor
condemn
lifelong
use
medic
new
object
develop
hiv
cure
exploit
divers
strategi
ultim
clear
latent
hiv
sanctuari
site
approach
consist
gene
silenc
genom
edit
review
issu
badia
et
al
provid
offtarget
immunogen
effect
avoid
effici
deliveri
achiev
sirnamedi
gene
silenc
move
research
medic
technolog
thank
posit
signal
clinic
trial
instanc
cancer
field
sirna
therapi
alreadi
clinic
evalu
viru
infect
similarli
discoveri
may
reshap
molecular
biolog
practic
research
laboratori
also
creat
revolutionari
therapi
cure
hiv
chronic
infect
among
other
hepat
b
hbv
hepat
c
hcv
epsteinbarr
viru
regulatori
issu
associ
clinic
use
current
address
specif
virus
hurdl
choos
best
viral
target
effici
deliveri
viral
nonvir
vector
develop
resist
remain
solv
path
toward
hbv
cure
review
protzer
et
al
viru
chronic
infect
million
peopl
fifti
year
discoveri
hbv
remain
first
caus
hepatocellular
carcinoma
worldwid
cancer
rank
third
term
mortal
antihbv
nucleo
ide
drug
achiev
viral
suppress
remiss
liver
diseas
treat
patient
thu
decreas
elimin
incid
hepatocellular
carcinoma
unfortun
antivir
erad
hbv
coval
close
circular
ccc
dna
infect
cell
impli
lifelong
therapi
prevent
viru
rebound
henc
hbv
research
current
aim
find
hbv
cure
either
decreas
elimin
intrahepat
pool
cccdna
silenc
transcript
activ
option
earli
clinic
preclin
evalu
categor
direct
antivir
immunotherapeut
strategi
first
class
includ
hbv
entri
blocker
drug
destroy
silenc
cccdna
sirna
antisens
oligonucleotid
target
viral
transcript
nucleocapsid
assembl
modul
approach
decreas
hbsag
releas
serum
immunotherapi
chronic
hbv
infect
tolllik
receptor
agonist
among
explor
agent
clinic
trial
lack
tcell
respons
chronic
liev
naesen
senior
investig
rega
institut
leuven
head
influenza
viru
research
team
work
antivir
drug
discoveri
year
current
focu
inhibitor
influenza
viru
entri
viral
polymeras
appli
virolog
biochem
assay
design
new
antivir
concept
defin
mechan
action
translat
knowledg
better
understand
viral
replic
strategi
besid
research
function
liev
naesen
sinc
associ
professor
ku
leuven
univers
leuven
teach
cours
medic
virolog
hbv
partli
due
express
coinhibitori
receptor
immunosuppress
cytokin
novel
anticanc
concept
consist
checkpoint
inhibitor
restor
antitumor
immun
yield
promis
data
hbv
anim
model
ex
vivo
studi
human
outcom
therapeut
vaccin
disappoint
yet
new
vaccin
formul
clinic
evalu
ultim
achiev
hbv
cure
like
need
combin
antivir
therapeut
block
multipl
step
hbv
lifecycl
immunomodulatori
strategi
restor
antivir
immun
respons
explain
glenn
et
al
hbv
patient
coinfect
hepat
delta
viru
hdv
requir
therapi
pegyl
interferonalpha
pegifna
yet
success
rate
low
sever
medic
clinic
trial
mainli
combin
pegifna
andor
nucleo
ide
analogu
includ
hbvhdv
entri
inhibitor
nucleic
acid
polym
drug
inhibit
releas
hbsag
prenyl
inhibitor
larg
hdv
antigen
analog
hiv
hcv
issu
underw
medic
revolut
thank
enorm
success
drug
discoveri
last
decad
sever
direct
act
antivir
daa
target
key
step
viral
life
cycl
develop
posit
vitro
data
confirm
clinic
studi
demonstr
high
cure
rate
excel
safeti
profil
current
promis
drug
combin
allow
hcv
elimin
patient
receiv
cours
oral
therapi
still
discuss
aghemo
et
al
patient
popul
problemat
infect
hcv
genotyp
one
show
daa
resist
patient
endstag
liver
diseas
obstacl
may
hope
solv
new
gener
antivir
approv
next
month
expect
one
remain
medicoeconom
problem
relat
high
cost
hcv
medic
requir
wide
hcv
screen
program
order
treat
infect
patient
clear
viru
occurr
sever
liver
diseas
complic
global
effort
made
facilit
medic
access
differ
area
affect
hcv
anoth
lesson
drawn
hiv
field
univers
virus
appear
vast
sourc
threat
limit
control
even
intens
surveil
seem
unabl
prevent
outbreak
emerg
potenti
pandem
virus
ebola
crisi
pain
wakeup
call
iron
fuel
new
research
financi
invest
develop
vaccin
rel
infrequ
yet
seriou
emerg
viral
pathogen
review
ebola
viru
duraffour
et
al
assess
field
expertis
clinic
find
antivir
antibodybas
trial
investig
favipiravir
zmapp
moreov
author
comment
posit
result
achiev
provid
ebola
victim
optim
standard
care
coupl
biochem
laboratori
test
henc
restor
volum
electrolyt
balanc
final
address
problem
conduct
welldesign
trial
catastroph
outbreak
resourcelimit
set
past
year
zoonot
viru
infect
continu
center
radar
mosquitoborn
dengu
viru
caus
million
infect
year
sinc
first
dengu
vaccin
approv
endem
countri
recommend
geograph
area
epidemiolog
data
indic
high
burden
diseas
two
flavivirus
came
spotlight
outbreak
vaccineprevent
yellow
fever
viru
angola
congo
brazil
rise
zika
viru
latin
america
associ
alarm
incid
microcephali
congenit
zika
viru
infect
panflaviviru
antivir
drug
could
tremend
global
impact
human
health
one
potenti
target
zika
viru
methyltransferas
involv
format
viral
mrna
cap
crystal
structur
sensit
class
dual
zikadengu
viru
inhibitor
recent
reveal
canard
cowork
review
decroli
canard
describ
divers
cap
pathway
util
virus
mani
wellsuit
antivir
drug
design
instanc
fragmentbas
silico
approach
author
analyz
biochem
structur
divers
viral
cap
pathway
enzym
impact
interf
viral
mrna
cap
eg
induc
host
innat
immun
relev
antivir
research
exemplifi
prototyp
inhibitor
report
literatur
chikungunya
viru
chikv
anoth
mosquitoborn
emerg
pathogen
recent
antivir
research
yield
promis
track
abdelnabi
et
al
review
direct
act
antivir
host
target
agent
evalu
also
discuss
strategi
antivir
therapi
period
chikv
viremia
short
treatment
start
quickli
diseas
onset
viral
load
reduct
may
expect
decreas
transmiss
effici
viru
mosquito
likelihood
develop
chronic
chikv
diseas
higher
person
sever
symptom
acut
phase
infect
administr
potent
antivir
drug
acut
phase
may
decreas
risk
develop
chronic
diseas
interest
see
whether
chikv
inhibitor
may
benefici
effect
develop
chronic
arthriti
agent
may
potenti
also
use
household
prophylaxi
perspect
author
also
describ
potenti
broader
inhibitor
panalphaviru
activ
besid
zoonot
virus
mention
sever
viru
infect
still
need
antivir
therapi
bauer
et
al
review
current
statu
enteroviru
inhibitor
genu
picornavirida
includ
import
pathogen
polioviru
increasingli
detect
enterovirus
omnipres
rhinovirus
moment
antivir
therapi
avail
enterovirus
besid
viru
capsid
binder
eg
pleconaril
develop
time
ago
sever
target
explor
enterovir
proteas
viral
rnadepend
rnapolymeras
viral
atpas
virion
assembl
besid
author
explain
relev
address
host
factor
pivot
role
enteroviru
replic
phosphatidylinositol
type
iiib
oxysterolbind
protein
cyclophilin
toxic
avoid
address
host
factor
could
advantag
entail
broad
antienteroviru
activ
obviou
bonu
commerci
develop
final
issu
featur
three
contribut
respiratori
viru
infect
start
challeng
hosttarget
concept
airway
proteas
inhibitor
activ
influenzavirus
coronavirus
parainfluenzavirus
laport
naesen
review
current
still
incomplet
knowledg
trypsinlik
serin
proteas
respons
activ
influenza
hemagglutinin
describ
principl
design
substratebas
eg
peptidomimet
alloster
inhibitor
relev
airway
proteas
main
challeng
select
versu
irrelev
structur
relat
host
serin
proteas
subsequ
corti
et
al
provid
time
updat
broadli
neutral
antibodi
influenza
hemagglutinin
besid
review
antibodi
bind
site
hemagglutinin
subtyp
coverag
author
thoroughli
explain
latest
insight
antivir
immunolog
eg
fabmedi
fcmediat
mechan
action
well
statu
antihemagglutinin
antibodi
phase
clinic
trial
monoclon
antibodi
could
pioneer
new
drug
class
influenza
interestingli
second
antibodybas
antivir
therapi
commerci
palivizumab
prophylaxi
respiratori
syncyti
viru
rsv
infect
latter
viru
address
rezae
et
al
describ
clinic
pipelin
rsv
prevent
passiv
activ
immun
review
cover
divers
liveattenu
vectorbas
subunit
rsv
vaccin
variou
stage
clinic
evalu
infant
pregnant
women
elderli
person
analysi
includ
vaccin
efficaci
toler
safeti
issu
genet
basi
attenu
temperaturesensit
virus
result
preclin
anim
studi
given
rsv
bronchiol
global
major
medic
problem
particularli
vulner
infant
possibl
impact
approv
rsv
vaccin
overestim
nowaday
rang
antivir
drug
exist
combat
infect
herpesvirus
hiv
hepat
b
c
viru
influenza
viru
hand
still
numer
medic
import
virus
effect
therapi
exist
disturbingli
list
includ
widespread
potenti
pandem
virus
besid
seriou
pathogen
like
ebola
yellow
fever
zika
viru
time
reemerg
long
vaccin
nonexist
insuffici
use
given
sophist
research
technolog
wide
access
crystallographi
silico
design
smallmolecul
ligand
recombin
protein
engin
gene
silenc
genom
edit
tool
develop
effect
therapi
old
bug
creativ
face
new
one
